Effect of Sustained Elevated Gastric pH Levels on Gefitinib Exposure
Authors:
- 8 February 2017
- journal article
- research article
- Published by Wiley in Clinical Pharmacology in Drug Development
- Vol. 6 (5) , 517-523
Abstract
This open‐label, randomized, phase 1 crossover study investigated the effect of elevated gastric pH level (>5) on the relative bioavailability and pharmacokinetic profile of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib. Healthy male volunteers (n = 26) were randomized to gefitinib 250 mg (fasted), either alone on day 1 (unmodified gastric pH) or 1 hour following the second of 2 oral doses of the H2‐receptor antagonist ranitidine 450 mg (elevated gastric pH). After a 3‐week washout period, volunteers crossed to the other treatment. The geometric least‐squares (GLS) mean AUC0–∞ and Cmax for gefitinib were reduced by 47% and 71%, respectively, under conditions of sustained elevated gastric pH; for both parameters, the 90%CI for the ratio of the GLS means lay below the prespecified lower limit. Median tmax was delayed from 5 to 6 hours. Mean t1/2 was similar under both gastric pH conditions. No serious adverse events were reported. The bioavailability of a single oral gefitinib 250‐mg dose was reduced by approximately 50% when gefitinib was administered under conditions of sustained elevated gastric pH.Keywords
Funding Information
- AstraZeneca
This publication has 27 references indexed in Scilit:
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsOncogene, 2009
- Gefitinib in lung cancer therapy: Clinical results, predictive markers of response and future perspectivesCancer Biology & Therapy, 2009
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- Pharmacokinetic Drug Interactions of Gefitinib with Rifampicin, Itraconazole and MetoprololClinical Pharmacokinetics, 2005
- Single-Dose Clinical Pharmacokinetic Studies of GefitinibClinical Pharmacokinetics, 2005
- Development of the Novel Biologically Targeted Anticancer Agent GefitinibClinical Cancer Research, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004